Regenerative Medicine and Stem Cells Technologies

Mastitis is the most expensive disease in the dairy industry. Each clinical case can cost a dairy farmer more than $400 and damages both the cows future output as well as her comfort.

The researchers studded the surface of the liposome nanoparticles with circular, lasso-like tumor-targeting molecules that helped pull the nanoparticles inside the tumors.

Researchers at the University of Washington, Seattle, have used human embryonic stem cell–derived cardiomyocytes (hESC-CMs) to restore heart function in macaque monkeys with heart failure.

The first symposium on “muscle disorders, stem cells and regenerative medicine” was held with the cooperation of stem cells sciences and technologies development headquarter.

Mesenchymal stem cells (MSCs) are an attractive cell type for cartilage repair that can undergo chondrogenesis in a variety of three dimensional (3D) scaffolds. Hyaluronic acid (HA) hydrogels provide a biologically relevant interface for cell encapsulation.

A challenge in regenerative medicine is governed by the need to have control over the fate of stem cells that is regulated by the physical and chemical microenvironment in vitro and in vivo. The differentiation of the stem cells into specific lineages is commonly guided by use of specific culture media.

University of California, Irvine stem cell researcher Magdalene J. Seiler, PhD, has received a $4.8 million grant from the California Institute of Regenerative Medicine (CIRM) to continue developing a stem cell-based therapy for a vision-robbing eye disease, retinitis pigmentosa. The therapy may also be applicable to macular degeneration.

A new device that can increase the production of viable neural stem cells may change the landscape of neural stem cell therapies as potential strategies for neurodegenerative and chronic diseases, including Parkinson’s and Alzheimer’s.

Mustang Bio, Inc. (NASDAQ:MBIO), a Fortress Biotech (NASDAQ:FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology, today announced that it has opened a CAR T cell therapy manufacturing facility at UMass Medicine Science Park in Worcester, Mass. The 27,000 sq. ft. facility will support the clinical development and commercialization of Mustang’s CAR T product candidates and enable proprietary cell therapy research.

Ischemic heart failure still displays the highest mortality. An early boost of intracardiac regenerative key mechanisms and angiogenetic niche signaling in cardiac mesenchymal stem cells (MSCs) could improve myocardial infarction (MI) healing